Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer therapies - Moleculin Biotech/University of Texas M D Anderson Cancer Center

Drug Profile

Research programme: anticancer therapies - Moleculin Biotech/University of Texas M D Anderson Cancer Center

Alternative Names: 2-DG prodrug; CP2005; Degrasyns; Tyrphostins; WP 1122; WP 1234; WP 1732; WP1106; WP1129; WP1130

Latest Information Update: 30 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Jagiellonian University; Moleculin; Moleculin Biotech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Glycolysis inhibitors; Janus kinase-2 inhibitors; STAT3 transcription factor inhibitors; Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Glioblastoma; Pancreatic cancer
  • Research Eye neoplasms

Most Recent Events

  • 28 Nov 2018 Preclinical pharmacokinetics data in Pancreatic Cancer released by Moleculin Biotech
  • 15 Nov 2018 Moleculin Biotech announces intention to submit IND application to the US FDA
  • 15 Nov 2018 Moleculin Biotech files a request to US FDA for pre-IND meeting to seek guidance for WP 1732 developmet plan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top